/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
David Preiss is a clinical academic with qualifications as a Chemical Pathologist and a Metabolic Physician. He joined the Clinical Trial Service Unit, Oxford, in 2015. His major interests are the prevention of cardiovascular disease (CVD) and also microvascular complications of diabetes, with particular focus on lipid modification and glucose lowering. He is Chief Investigator for the LENS trial, testing the effect of fenofibrate on diabetic retinopathy progression. He is also Co-Principal Investigator on the EMPA-KIDNEY trial (SGLT2 inhibition in patients with chronic kidney disease) and Clinical Coordinator for the ORION-4 trial (PCSK9 synthesis inhibition in a secondary prevention population). He was awarded the University of Glasgow’s Bellahouston Medal for his PhD thesis which examined the links between glycaemia and CVD. He is a previous recipient of a EFSD Rising Star fellowship and also of the Royal College of Pathology’s Research Medal for Clinical Biochemistry.
